U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C43H69N11O3
Molecular Weight 788.0799
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VOXVOGANAN

SMILES

CC(C)(C)C1=C(C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCCC2=CC=CC=C2)C3=C(N1)C(=CC(=C3)C(C)(C)C)C(C)(C)C

InChI

InChIKey=ZVOYWSKEBVVLGW-ZDCRTTOTSA-N
InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1

HIDE SMILES / InChI

Molecular Formula C43H69N11O3
Molecular Weight 788.0799
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

LTX109 is a synthetic antimicrobial agent and is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent manner. LTX109 was in clinical phase II trials for topical treatment of infections of multiresistant bacterial strains. However, the further development of this drug apparently has been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed

Sample Use Guides

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA). Ascending dose study. Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2% LTX-109/placebo and finally group 3: 5% LTX-109/placebo dosed in each nostril TID for 3 consecutive days.
Route of Administration: Topical
LTX-109 demonstrated a MIC range of 2 to 4 μg/ml and dose-dependent rapid bactericidal activity against S. aureus.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:23:54 GMT 2023
Edited
by admin
on Fri Dec 15 15:23:54 GMT 2023
Record UNII
HO813QDF65
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VOXVOGANAN
INN  
Official Name English
voxvoganan [INN]
Common Name English
L-ARGININAMIDE, L-ARGINYL-2,5,7-TRIS(1,1-DIMETHYLETHYL)-L-TRYPTOPHYL-N-(2-PHENYLETHYL)-
Common Name English
LTX 109 [WHO-DD]
Common Name English
LTX-109
Code English
LTX109
Code English
Code System Code Type Description
FDA UNII
HO813QDF65
Created by admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
PRIMARY
DRUG BANK
DB12711
Created by admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
PRIMARY
SMS_ID
300000025934
Created by admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
PRIMARY
PUBCHEM
25242323
Created by admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
PRIMARY
CAS
1166254-80-3
Created by admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
PRIMARY
INN
12015
Created by admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID20151467
Created by admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
PRIMARY
NCI_THESAURUS
C188583
Created by admin on Fri Dec 15 15:23:54 GMT 2023 , Edited by admin on Fri Dec 15 15:23:54 GMT 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
Related Record Type Details
ACTIVE MOIETY